Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 85
Healthy Volunteers: t
View:
• History of COVID-19 infection
• Live within a geographically accessible area for follow-up
Locations
Other Locations
Australia
Baker Heart and Diabetes Institute
RECRUITING
Melbourne
Contact Information
Primary
Joel Smith, MSc
joel.smith@baker.edu.au
+61385321964
Backup
Thomas H Marwick, MD,PhD,MPH
tom.marwick@baker.edu.au
+61385321550
Time Frame
Start Date: 2021-11-18
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 820
Treatments
Experimental: Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)
1. Optimization of pharmacotherapy:~ This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.~2. Exercise intervention: Individualized training program will be provided by an exercise physiologist
Active_comparator: Usual care
All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).
Related Therapeutic Areas
Sponsors
Leads: Baker Heart and Diabetes Institute